Skip to content
Homepage
Author:
ExCellThera
Posted Date:
June 10, 2026
Zemcelpro® (UM171 Cell Therapy) licensing and supply agreements announced for Canada
ExCellThera
June 10, 2026
Zemcelpro® (dorocubicel) Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting
ExCellThera
March 10, 2026
Zemcelpro® (dorocubicel) receives NUB Status 1 in Germany
ExCellThera
February 16, 2026
